Want to see HK:2522 full AI Analyst Report?
2522 Stock Chart & Stats
HK$8.10
-HK$4.70(-9.29%)
At close: 4:00 PM EST
HK$8.10
-HK$4.70(-9.29%)
Day’s Range― - ―
52-Week RangeHK$3.74 - HK$24.44
Previous CloseN/A
Volume38.00K
Average Volume (3M)10.53M
Market Cap
HK$1.86B
Enterprise ValueHK$1.79B
Total Cash (Recent Filing)HK$626.16M
Total Debt (Recent Filing)HK$622.72M
Price to Earnings (P/E)380.0
Beta1.26
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding294,128,080
10 Day Avg. Volume6,254,929
30 Day Avg. Volume10,530,505
Financial Highlights & Ratios
PEG Ratio-6.51
Price to Book (P/B)1.33
Price to Sales (P/S)3.03
P/FCF Ratio45.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.92Price Target Upside34.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.06
Revenue Forecast (FY)HK$1.06B
Bulls Say, Bears Say
Bulls Say
Return To Revenue & ProfitabilityA return to positive revenue growth and a re-established net profit in 2025 indicate the business has regained demand or improved operations. Sustained top-line growth and the move back to profitability improve long-term margin leverage and increase the likelihood of durable cash generation over the next several quarters.
Manageable Balance-sheet LeverageA sizable equity base relative to debt provides a financial cushion that lowers refinancing risk and supports investment flexibility. This structural balance-sheet strength helps the company fund capex or working-capital needs without immediate pressure on operations or needing urgent external capital in the medium term.
Rebound In Operating Cash Flow And FCFA strong rebound in operating cash flow and return to positive free cash flow show improved cash conversion and internal funding capacity. Durable operating cash generation reduces dependence on external financing, enabling reinvestment in operations or selective growth initiatives over the coming months.
Bears Say
Volatile Free Cash FlowLarge swings in free cash flow reflect material sensitivity to capex or working-capital timing, making cash available to shareholders and for strategic projects unpredictable. That volatility complicates planning, raises execution risk, and can force reactive financing or spending cuts during downturns.
Earnings Quality And Profit VolatilitySharp multi-year swings in revenue and net income suggest earnings are sensitive to cyclical forces or one-off items. The very thin 2025 profit leaves margins fragile and increases the chance that small adverse changes will erase profitability, limiting reliable long-term return projections.
Rising Debt Year-over-yearAn increase in absolute debt raises leverage and interest-service obligations. Given the company’s uneven profitability and cash-flow volatility, rising debt amplifies financial risk, could constrain strategic flexibility, and increases vulnerability if operating performance weakens.
Jiangxi Rimag Group Co., Ltd. Class H News
2522 FAQ
What was Jiangxi Rimag Group Co., Ltd. Class H’s price range in the past 12 months?
Jiangxi Rimag Group Co., Ltd. Class H lowest stock price was HK$3.74 and its highest was HK$24.44 in the past 12 months.
What is Jiangxi Rimag Group Co., Ltd. Class H’s market cap?
Jiangxi Rimag Group Co., Ltd. Class H’s market cap is HK$1.86B.
When is Jiangxi Rimag Group Co., Ltd. Class H’s upcoming earnings report date?
Jiangxi Rimag Group Co., Ltd. Class H’s upcoming earnings report date is Sep 01, 2026 which is in 26 days.
How were Jiangxi Rimag Group Co., Ltd. Class H’s earnings last quarter?
Jiangxi Rimag Group Co., Ltd. Class H released its earnings results on Mar 31, 2026. The company reported -HK$0.036 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.036.
Is Jiangxi Rimag Group Co., Ltd. Class H overvalued?
According to Wall Street analysts Jiangxi Rimag Group Co., Ltd. Class H’s price is currently Undervalued.
Does Jiangxi Rimag Group Co., Ltd. Class H pay dividends?
Jiangxi Rimag Group Co., Ltd. Class H does not currently pay dividends.
What is Jiangxi Rimag Group Co., Ltd. Class H’s EPS estimate?
Jiangxi Rimag Group Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jiangxi Rimag Group Co., Ltd. Class H have?
Jiangxi Rimag Group Co., Ltd. Class H has 294,128,080 shares outstanding.
What happened to Jiangxi Rimag Group Co., Ltd. Class H’s price movement after its last earnings report?
Jiangxi Rimag Group Co., Ltd. Class H reported an EPS of -HK$0.036 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.68%.
Which hedge fund is a major shareholder of Jiangxi Rimag Group Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2522
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jiangxi Rimag Group Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.95%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
32.16%
Trailing 12-Months
Company Description
Jiangxi Rimag Group Co., Ltd. Class H
Operating across China, Jiangxi Rimag Group Co., Ltd. specializes in providing medical imaging services. The company delivers a comprehensive suite of diagnostic imaging procedures, including MRI, CT, PET scans, X-rays, ultrasounds, and mammography, serving both patients and other healthcare sector clients. It also offers sophisticated imaging solution services. Additionally, Rimag Cloud provides various digital offerings such as cloud-based storage and film modules, a cloud radiology information system (RIS), a cloud Picture Archive and Communication System (PACS), alongside modules for AI integration and operational management within imaging platforms. The firm also oversees and manages a medical imaging platform that hosts a diverse range of imaging-related services. Supporting its activities is a dedicated research and development center, and it further engages in the distribution of medical equipment and related consumables. Established in 2014, the company maintains its primary office in Beijing, China.
2522 Stock 12 Month Forecast
Average Price Target
HK$10.92
▲(34.81% Upside)
Technical Analysis
EuroEyes International Eye Clinic Limited
―
Chaoju Eye Care Holdings Ltd.
―
Yonghe Medical Group Co., Ltd.
―
C-MER Eye Care Holdings Limited
―
Town Health International Medical Group Ltd.
―